Cost-effectiveness analysis of prenatal screening and vaccination against hepatitis B virus : the case of Belgium.
The study examines the cost-effectiveness of screening pregnant women in Belgium for the presence of hepatitis B virus (HBV) and of vaccinating the newborns if necessary.
The alternative strategy considered is « doing nothing ».
The rate of carriership among a sample of pregnant women in Belgium amounts to 0.67%. If a pregnant woman is a carrier of the virus, there is an average probability of 30% that she will transmit the virus to her newborn.
Later in life, this baby will be at risk from serious complications, such as chronic active hepatitis, cirrhosis and primary hepatocellular cancer.
However, medical costs will be induced by screening and vaccination campaigns, lab-tests, vaccine costs, etc.
On the other hand, resources will be saved by the prevention of severe complications of the disease.
Mots-clés Pascal : Hépatite virale B, Prénatal, Programme sanitaire, Belgique, Europe, Vaccination, Dépistage, Appareil digestif pathologie, Foie pathologie, Virose, Infection, Prévention, Nouveau né, Homme, Analyse coût efficacité, Economie santé, Arbre décision, Transmission, Gestation
Mots-clés Pascal anglais : Prenatal, Sanitary program, Belgium, Europe, Vaccination, Medical screening, Digestive diseases, Hepatic disease, Viral disease, Infection, Prevention, Newborn, Human, Cost efficiency analysis, Health economy, Decision tree, Transmission, Pregnancy
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 93-0510352
Code Inist : 002B05C02G. Création : 199406.